Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms [DISEASES]"'
Autor:
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, Kathleen Moore, Ana Oaknin, Ignacio Romero, Sami Diab, Larry J Copeland, Bradley J Monk, Robert L Coleman, Thomas J Herzog, Jonathan Siegel, Linda Kasten, Andreas Schlicker, Anke Schulz, Karl Köchert, Annette O Walter, Barrett H Childs, Cem Elbi, Iurie Bulat
Publikováno v:
Scientia
ObjectivesAnetumab ravtansine is an antibody-drug conjugate consisting of a fully human anti-mesothelin monoclonal antibody conjugated to cytotoxic maytansinoid tubulin inhibitor DM4. Mesothelin is highly expressed in ovarian cancer. This phase Ib st
Autor:
Fernandez-Serra, Antonio, López-Reig, Raquel, Márquez, Raúl, Gallego, Alejandro, De Sande-González, Luis Miguel, Yubero Esteban, Alfonso, OAKNIN, ANA
Publikováno v:
Scientia
Genomic instability; Machine learning Inestabilidad genómica; Aprendizaje automático Inestabilitat genòmica; Aprenentatge automàtic Genomic Instability (GI) is a transversal phenomenon shared by several tumor types that provide both prognostic an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3991::94cd02cc9b31e807ec9ecb23f6ca0321
https://hdl.handle.net/11351/9746
https://hdl.handle.net/11351/9746
Autor:
Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason A. Konner, Margarita Romeo Marin, Philipp Harter, Conleth G. Murphy, Jiuzhou Wang, Elizabeth Noble, Brooke Esteves, Michael Method, Robert L. Coleman
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
Scientia
Scientia
PURPOSE Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c10e3c1896de442760b90bcffde4d772
https://lirias.kuleuven.be/handle/20.500.12942/715272
https://lirias.kuleuven.be/handle/20.500.12942/715272
Autor:
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Amit Oza, Antonio González-Martín, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, John McNamara, Elizabeth S. Lowe, Mei-Lin Ah-See, Kathleen N. Moore
Publikováno v:
Scientia
Disilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, B, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Oza, A, González-martín, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Mcnamara, J, Lowe, E S, Ah-see, M & Moore, K N 2022, ' Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.22.01549
Disilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, B, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Oza, A, González-martín, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Mcnamara, J, Lowe, E S, Ah-see, M & Moore, K N 2022, ' Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.22.01549
PURPOSE In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986 ), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients with newly diagnosed advanced ovar
Autor:
Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis, Gina M. Mantia-Smaldone, Peter C. Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Kathleen N. Moore, David M. O'Malley
Publikováno v:
Scientia
Bevacizumab; Folate receptor alpha; Platinum-resistant ovarian cancer Bevacizumab; Receptor de folato alfa; Cáncer de ovario resistente al platino Bevacizumab; Receptor de folat alfa; Càncer d'ovari resistent al platí Purpose Evaluate the antitumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9563699908903c82ae422d0b10f7eaa2
https://hdl.handle.net/11351/9113
https://hdl.handle.net/11351/9113
Autor:
Bradley J. Monk, Christine Parkinson, Myong Cheol Lim, David M. O'Malley, Ana Oaknin, Michelle K. Wilson, Robert L. Coleman, Domenica Lorusso, Paul Bessette, Sharad Ghamande, Athina Christopoulou, Diane Provencher, Emily Prendergast, Fuat Demirkiran, Olga Mikheeva, Oladapo Yeku, Anita Chudecka-Glaz, Michael Schenker, Ramey D. Littell, Tamar Safra, Hung-Hsueh Chou, Mark A. Morgan, Vít Drochýtek, Joyce N. Barlin, Toon Van Gorp, Fred Ueland, Gabriel Lindahl, Charles Anderson, Dearbhaile C. Collins, Kathleen Moore, Frederik Marme, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca S. Kristeleit
Publikováno v:
Scientia
PURPOSE ATHENA (ClinicalTrials.gov identifier: NCT03522246 ) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::312a6e609ec98f3f3c5b48462663544d
https://hdl.handle.net/11351/8726
https://hdl.handle.net/11351/8726
Autor:
Zaida Garcia-Casado, Ana Oaknin, Marta Mendiola, Gorka Alkorta-Aranburu, Jose Ramon Antunez-Lopez, Gema Moreno-Bueno, Jose Palacios, Alfonso Yubero, Raul Marquez, Alejandro Gallego, Ana Beatriz Sanchez-Heras, Jose Antonio Lopez-Guerrero, Cristina Perez-Segura, Pilar Barretina-Ginesta, Jesus Alarcon, Lydia Gaba, Antonia Marquez, Judit Matito, Juan Cueva, Isabel Palacio, Maria Iglesias, Angels Arcusa, Luisa Sanchez-Lorenzo, Eva Guerra-Alia, Ignacio Romero, Ana Vivancos
Publikováno v:
Scientia
Journal of Personalized Medicine; Volume 12; Issue 11; Pages: 1842
Journal of Personalized Medicine; Volume 12; Issue 11; Pages: 1842
Germline and tumor BRCA testing constitutes a valuable tool for clinical decision-making in the management of epithelial ovarian cancer (EOC) patients. Tissue testing is able to identify both germline (g) and somatic (s) BRCA variants, but tissue pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bac3e9951412027604b384b35ccd4809
https://hdl.handle.net/11351/8598
https://hdl.handle.net/11351/8598
Autor:
Bruna Palma Matta, Renan Gomes, Daniel Mattos, Renata Olicio, Caroline Macedo Nascimento, Gerson Moura Ferreira, Ayslan Castro Brant, Mariana Boroni, Carolina Furtado, Valdirene Lima, Miguel Ângelo Martins Moreira, Anna Cláudia Evangelista dos Santos
Publikováno v:
Scientia
Cancer; Genetics; Risk factors Cáncer; Genética; Factores de riesgo Càncer; Genètica; Factors de risc Several studies have demonstrated the cost-effectiveness of genetic testing for surveillance and treatment of carriers of germline pathogenic va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61e5a29721402a719d36bc0860c36acb
https://hdl.handle.net/11351/8731
https://hdl.handle.net/11351/8731
Autor:
Gabe S. Sonke, Cara Mathews, Carol Aghajanian, Nicoletta Colombo, Alexandra Leary, Ana Oaknin, Joyce F. Liu, Giovanni Scambia, William H. Bradley, Elizabeth S. Lowe, Jae Weon Kim, Alla Lisyanskaya, Antonio González-Martín, Anne Floquet, Michael Friedlander, Kathleen N. Moore, Ralph Bloomfield, Amit M. Oza, Charlie Gourley, Susana Banerjee, Paul DiSilvestro
Publikováno v:
Colombo, N, Moore, K, Scambia, G, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Banerjee, S, Oza, A, González-martín, A, Aghajanian, C, Bradley, W H, Kim, J, Mathews, C, Liu, J, Lowe, E S, Bloomfield, R & Disilvestro, P 2021, ' Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial ', Gynecologic Oncology . https://doi.org/10.1016/j.ygyno.2021.07.016
Scientia
Scientia
Olaparib; Ovarian cancer; Tolerability Olaparib; Cáncer de ovarios; Tolerabilidad Olaparib; Càncer d'ovaris; Tolerabilitat Objectives In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a substantial progression-free survival
Autor:
Capoluongo ED, B, Pellegrino, Arenare L, Califano D, Scambia G, L, Beltrame, V, Serra, Scaglione GL, Spina A, Cecere SC, De Cecio R, N, Normanno, N, Colombo, Lorusso D, Russo D, Nardelli C, M, D'Incalci, Llop-Guevara A, Pisano C, G, Baldassarre, Mezzanzanica D, Artioli G, Setaro M, Tasca G, C, Roma, Campanini N, Cinieri S, A, Sergi, Musolino A, Perrone F, Chiodini P, S, Marchini, Pignata S
Publikováno v:
Scientia
Molecular testing; Ovarian cancer Proves moleculars; Càncer d'ovaris Pruebas moleculares; Cáncer de ovarios Background The detection of homologous recombination deficiency (HRD) can identify patients who are more responsive to platinum and poly ADP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdf39ab4ed238d4e922aed12d4c930dd
https://hdl.handle.net/11351/8362
https://hdl.handle.net/11351/8362